Goodwin’s Life Sciences team has advised Tenpoint Therapeutics, Ltd. on a major financing milestone, supporting the company in securing a total of $235 million through a combination of equity and debt funding. The transaction strengthens Tenpoint’s balance sheet and provides substantial capital to support the commercialization of its lead ophthalmology product and broader growth strategy.
The funding includes a successful Series B preferred stock financing alongside a significant non-dilutive credit facility, highlighting strong investor confidence in Tenpoint’s science, leadership, and commercial vision.
Deal
Tenpoint Therapeutics raised $85 million through its Series B preferred stock financing. The round was led by prominent investors including Janus Henderson, EQT Nexus, Hillhouse, and the British Business Bank. The financing also saw continued support from existing investors such as EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, and Wille.
In addition to the equity raise, Tenpoint entered into a $150 million senior secured term loan facility with Hercules Capital. This non-dilutive financing structure allows the company to access significant capital while limiting shareholder dilution, offering greater financial flexibility as it advances commercialization efforts.
Company
Tenpoint Therapeutics Ltd. is a global biotechnology company focused on developing and commercializing therapies for age-related eye conditions. Its lead product, YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, is the first and only dual-agent eye drop approved for the treatment of presbyopia.
Presbyopia is a widespread condition associated with aging, affecting nearly 128 million people in the United States and close to 2 billion individuals worldwide. By addressing a large and growing patient population, Tenpoint is positioned within a significant global ophthalmology market.
Product
YUVEZZI represents a differentiated approach to presbyopia treatment by combining two active agents in a single eye drop. The therapy is designed to improve near vision while maintaining distance vision, offering a non-invasive alternative to glasses, contact lenses, or surgical procedures.
Tenpoint’s strategy emphasizes understanding real-world patient needs and working closely with eye care professionals to ensure effective adoption and long-term impact in clinical practice.
Impact
The $235 million financing package provides Tenpoint with the resources needed to support commercial launch activities, expand market access, and invest in future pipeline opportunities. The mix of equity and debt financing reflects a balanced capital strategy that supports growth while managing dilution and financial risk.
This transaction also underscores continued investor appetite for late-stage life sciences companies with approved products and clear commercial pathways.
Advisors
Goodwin’s Life Sciences team played a central role in advising Tenpoint throughout the transaction. The team was led by David Mardle, Matthew Lee, Kingsley Taft, Heidi McNally, Harriet Worthington, Gaspard du Chaffaut, Olly Watt, Kevin Grumberg, Richard Garvan, Sunnie Zhao, and Sarah Mackin.
They were supported by Lindsay Thomas, Ella Bedecarre, Simon Fulbrook, Nadim Islam, and Damian Molineus, whose contributions were instrumental in the successful completion of both the equity financing and credit facility.
The transaction highlights Goodwin’s continued strength in advising innovative biotechnology companies on complex, high-value financings. For Tenpoint Therapeutics, the funding marks an important step forward in its mission to bring meaningful innovation to the aging eye and improve vision for millions of patients worldwide.
FAQs
How much capital did Tenpoint Therapeutics raise?
Tenpoint secured a total of $235 million.
Who led Tenpoint’s Series B financing?
Janus Henderson, EQT Nexus, Hillhouse, and British Business Bank.
What is YUVEZZI used to treat?
It is used to treat presbyopia.
What type of debt facility did Tenpoint secure?
A $150 million non-dilutive senior secured term loan.
